“spinraza” Archives

in
Entry Author Date Location
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy 08/07/20 National
FDA: Despite “Manipulated” Data, $2M Gene Therapy Should Stay on Market 08/06/19 National
Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More 07/05/19 National
Second US Gene Therapy, Approved for Rare Muscle Disease, to Cost $2M 05/24/19 National
SMA, Migraine Data Lead Neuro Highlights from AAN Meeting 05/07/19 National
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More 05/03/19 National
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease? 05/02/19 National
Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience 04/24/19 Boston
How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy 04/15/19 National
Report: Biogen, Novartis Should Drop Prices of Billon-Dollar SMA Drugs 04/04/19 Boston
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More 10/26/18 National
With $90M Round, Stoke Eyes a “Spinraza For Epilepsy” And a 2019 IPO 10/23/18 Boston
Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End 10/19/18 National
Spinraza Inventors Take Home $3M Breakthrough Prize in Life Sciences 10/17/18 National
Bio Roundup: Big Approvals, ICER Influence, Drug-Price Pushback & More 08/17/18 National
Biotech IPOs Roll On as Kiniksa, Scholar Rock Get $227M Combined 05/24/18 Boston
SMA Day: AveXis Gene Therapy Creeps Forward as Biogen Drug’s Sales Slow 04/25/18 Boston
Biogen Pays $1B to Broaden Ionis Pact, Betting More on RNA Drugs 04/20/18 Boston
Novartis Bets $8.7B on AveXis’s Gene Therapy for Spine Disease 04/09/18 National
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms 03/15/18 Boston
Disney, Family Offices Back Second Bio Startup from Tech Entrepreneur Haney 01/23/18 Boston
15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) 12/04/17 National
Ed Kaye on Sarepta’s Duchenne Quest, Rising to CEO & His New Startup 11/20/17 Boston
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise 07/25/17 Boston
Duchenne, SMA, and the Rise of Patient Power at “What’s Hot” on May 11 04/27/17 Boston
Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug? 04/26/17 Boston
Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More 04/21/17 National
“Our Son’s Fate”: Parents Fighting for Kids’ Spine Drug Eye New Data 04/20/17 Boston
Page 1 of 2 next page »